Orchid Pharma

830.05
-43.45
(-4.97%)
Market Cap
4,209.94 Cr
EPS
19.06
PE Ratio
40.48
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,997.40
52 Week low
800.00
PB Ratio
3.65
Debt to Equity
0.25
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy100.00 %
100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,676.85 4,02,332.48 33.68 49,887.20 12.06 9,648 13.77 51.48
5,667.15 1,50,445.03 71.18 8,184.00 0.89 1,600 64.53 47.74
1,454.30 1,17,451.31 23.41 26,520.70 14.17 4,155 47.38 50.99
3,096.50 1,04,799.63 55.61 10,785.70 11.59 1,656 13.54 51.13
1,105.15 92,214.92 17.35 28,905.40 12.36 5,578 1.69 29.06
1,966.70 89,720.37 31.45 20,141.50 19.94 1,936 38.82 43.35
2,166.45 89,380.56 44.67 10,615.60 19.57 1,942 -16.38 30.70
888.25 89,378.73 19.97 19,831.50 13.82 3,831 29.92 42.12
1,107.90 64,347.01 17.97 29,559.20 17.55 3,169 -10.04 46.41
29,795.85 63,314.10 48.58 6,097.20 10.80 1,201 16.01 51.54
Growth Rate
Revenue Growth
24.06 %
Net Income Growth
72.28 %
Cash Flow Change
586.97 %
ROE
1.37 %
ROCE
-18.34 %
EBITDA Margin (Avg.)
10.70 %

Quarterly Financial Results

Quarterly Financials
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
141
138
137
93
120
110
105
131
95
196
164
180
134
171
169
251
185
207
228
231
252
230
226
Expenses
148
133
129
108
100
91
108
123
95
116
151
154
119
147
146
177
161
175
185
188
212
192
191
EBITDA
-7
6
7
-15
21
19
-3
8
0
79
13
26
15
24
23
74
24
32
43
42
40
38
35
Operating Profit %
-9 %
-1 %
0 %
-23 %
16 %
17 %
-5 %
-3 %
-3 %
9 %
7 %
13 %
10 %
11 %
9 %
16 %
12 %
12 %
16 %
13 %
13 %
14 %
12 %
Depreciation
31
32
32
23
30
30
29
20
20
20
20
27
22
18
8
7
8
8
9
8
8
9
9
Interest
0
0
3
1
14
13
13
12
11
10
7
5
8
9
8
8
6
4
4
4
4
3
4
Profit Before Tax
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-6
-14
-3
7
59
11
20
30
30
28
26
23
Tax
0
0
0
0
0
0
0
0
0
0
0
1
1
2
-1
0
1
0
1
-3
-1
-1
2
Net Profit
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-7
-15
-5
8
59
9
20
29
33
29
27
21
EPS in ₹
-4.32
-2.93
-3.11
-9.52
-5.55
-5.98
-10.96
-6.06
-7.57
12.10
-3.40
-1.61
-3.68
-1.32
1.86
14.49
1.85
4.30
6.18
6.81
5.79
5.37
4.10

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
Fixed Assets
1,795
1,637
1,497
1,386
1,256
858
670
584
573
620
Current Assets
1,278
1,251
675
679
768
569
550
398
501
791
Capital Work in Progress
282
280
288
272
278
26
7
10
47
31
Investments
0
0
1
1
1
0
15
46
44
46
Other Assets
1,985
1,945
1,470
1,467
1,542
576
544
472
561
857
Total Liabilities
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
Current Liabilities
1,123
1,338
1,510
2,013
2,346
175
142
241
372
260
Non Current Liabilities
2,609
2,475
2,212
1,905
1,436
519
442
222
165
124
Total Equity
329
49
-467
-792
-704
766
653
647
689
1,170
Reserve & Surplus
244
-40
-556
-881
-793
725
544
538
579
1,050
Share Capital
85
89
89
89
89
41
41
41
41
51

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
367
-76
-240
15
57
-2
-74
-11
18
-19
Investing Activities
1,334
-2
-176
-28
46
167
67
113
-31
-312
Operating Activities
-369
212
401
9
12
81
24
93
18
126
Financing Activities
-597
-286
-465
33
-0
-250
-165
-217
31
167

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
98.07 %
90.00 %
90.00 %
90.00 %
90.00 %
89.96 %
89.96 %
89.96 %
89.96 %
72.40 %
72.40 %
69.84 %
69.84 %
69.84 %
69.84 %
69.84 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.14 %
1.96 %
1.42 %
1.94 %
2.53 %
DIIs
1.00 %
3.44 %
3.35 %
3.35 %
2.97 %
2.97 %
2.98 %
3.94 %
2.62 %
13.49 %
9.88 %
14.50 %
17.73 %
18.93 %
18.29 %
18.99 %
Government
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.58 %
2.34 %
2.72 %
2.83 %
3.34 %
3.69 %
3.61 %
3.44 %
3.38 %
3.10 %
3.85 %
7.79 %
7.44 %
7.16 %
7.59 %
6.42 %
Others
0.35 %
4.22 %
3.89 %
3.79 %
3.65 %
3.34 %
3.44 %
2.66 %
4.03 %
11.02 %
13.87 %
3.74 %
3.03 %
2.65 %
2.35 %
2.22 %
No of Share Holders
30,343
33,379
34,798
33,535
33,698
33,679
32,717
30,894
29,523
29,039
29,197
36,931
36,720
34,695
36,363
34,158

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

Intimation Under Regulation 30- Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And Creditors
1 day ago
Announcement under Regulation 30 (LODR)-Credit Rating
5 days ago
Disclosure Regarding The Order Passed By Goods And Service Tax Department
Feb 28, 2025, 16:29
Disclosure Regarding The Order Passed By Goods And Service Tax Department
Feb 28, 2025, 16:29
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 19, 2025, 17:58
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Feb 15, 2025, 16:05
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Feb 12, 2025, 19:28
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 12, 2025, 18:31
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Feb 12, 2025, 17:08
Statement Of Deviation Or Variation For The Quarter-III Of F.Y.2024-25 Ended On December 31 2024.
Feb 12, 2025, 17:00
Integrated Filing (Financial)
Feb 12, 2025, 16:54
Announcement under Regulation 30 (LODR)-Investor Presentation
Feb 12, 2025, 15:55
Outcome Of The Board Meeting Held For Inter Alia Consideration And Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On Decemb
Feb 12, 2025, 15:42
Board Meeting Outcome for Outcome Of Board Meeting
Feb 12, 2025, 15:35
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 06, 2025, 18:13
Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On February 12 2025
Feb 06, 2025, 18:00
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 13, 2025, 18:26
Closure of Trading Window
Dec 30, 2024, 17:50
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Nov 15, 2024, 13:10
Newspaper Publication Of Unaudited Limited ReviewedFinancial Results (Standalone & Consolidated) For Quarter- II And Half Year Ended On September 30, 2024 Of Financial Year 2024-25
Nov 12, 2024, 16:00
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Nov 11, 2024, 18:55
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nov 11, 2024, 18:31
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Nov 11, 2024, 18:11
Statement Of Deviation Or Variation For The Quarter Ended On September 30, 2024
Nov 11, 2024, 15:41
Announcement under Regulation 30 (LODR)-Investor Presentation
Nov 11, 2024, 15:32
Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2024
Nov 11, 2024, 15:10
Board Meeting Outcome for Outcome Of Board Meeting Held On November 11, 2024
Nov 11, 2024, 14:57
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Nov 06, 2024, 15:53
Board Meeting Intimation for Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended On September 30, 2024
Nov 05, 2024, 17:40
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 14, 2024, 16:24
Intimation Related To The Scheme Of Amalgamation Of DhanukaLaboratories Limited ('Amalgamating Company') With Orchid Pharma Limited ('Amalgamated Company') And Their Respective Shareholders And Creditors ('The Scheme') Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 '(SEBI Listing Regulations)', As Amended.
Sep 27, 2024, 17:52
Intimation Of Email Received From BSE For Warning Letter Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Sep 27, 2024, 16:47
Email Received From NSE Regarding Warning Letter Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI LODR )
Sep 26, 2024, 16:04
Closure of Trading Window
Sep 25, 2024, 17:51
Investor Roadshow Scheduled To Be Held On September 18, 2024
Sep 11, 2024, 13:43
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Sep 03, 2024, 15:44
Disclosure Regarding The Order Passed By Goods And Service Tax Department
Aug 22, 2024, 18:33
Chairman Speech- 31St Annual General Meeting Of Orchid Pharma Limited Held On August 21, 2024
Aug 22, 2024, 12:36
Voting Results For The 31St Annual General Meeting Of Orchid Pharma Limited
Aug 21, 2024, 21:17
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Aug 21, 2024, 21:11
Shareholder Meeting / Postal Ballot-Outcome of AGM
Aug 21, 2024, 20:40
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Aug 17, 2024, 19:00
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 14, 2024, 14:01
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aug 14, 2024, 13:41
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Aug 13, 2024, 20:13
Monitoring Agency Report Of The Company For The Quarter-1 Of Financial Year 2024-25, Ended On June 30, 2024
Aug 13, 2024, 20:03
Announcement under Regulation 30 (LODR)-Investor Presentation
Aug 13, 2024, 14:54
Statement Of Deviation And Variation For Qtr Ended June 2024
Aug 12, 2024, 19:38
Board Meeting Outcome for Financial Results For June 2024
Aug 12, 2024, 19:32
Financial Results For The Qtr June 2024
Aug 12, 2024, 19:29

Company Filings to Exchanges

Technical Indicators

RSI(14)
Neutral
30.07
ATR(14)
Less Volatile
69.22
STOCH(9,6)
Neutral
29.70
STOCH RSI(14)
Neutral
73.79
MACD(12,26)
Bullish
17.48
ADX(14)
Strong Trend
40.03
UO(9)
Bearish
41.52
ROC(12)
Downtrend And Accelerating
-0.12
WillR(14)
Neutral
-72.05